Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics

Biomaterials

Volumn 156, Issue , 2018, Pages 217-237

  Overchuk, Marta ^a   Zheng, Gang ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer theranostics; Drug delivery; Nanomedicine; Tumor microenvironment

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; NANOPARTICLES; ONCOLOGY; TARGETED DRUG DELIVERY; TUMORS;

CRITICAL PERSPECTIVES; DRUG PENETRATION; OVERCOMING OBSTACLES; PATHOPHYSIOLOGY; SCIENTIFIC COMMUNITY; THERANOSTICS; THERAPEUTIC AGENTS; TUMOR MICROENVIRONMENT;

MEDICAL NANOTECHNOLOGY;

GLUTATHIONE; LACTIC ACID; NANOPARTICLE;

ACIDITY; B LYMPHOCYTE; BIOACCUMULATION; CANCER ASSOCIATED FIBROBLAST; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL DEATH; CHEMICAL MODIFICATION; DRUG DELIVERY SYSTEM; ECHOGRAPHY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; EXTRAVASATION; GLYCOSYLATION; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INTRACELLULAR TRANSPORT; LIGAND BINDING; LIGHT EXPOSURE; MALIGNANT HYPERTHERMIA; MALIGNANT TRANSFORMATION; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PARTICLE SIZE; PATHOPHYSIOLOGY; PERICYTE; PHOTODYNAMIC THERAPY; PRESSURE GRADIENT; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; STIMULUS RESPONSE; STROMA CELL; SURFACE CHARGE; SURFACE PROPERTY; T LYMPHOCYTE; THERANOSTIC NANOMEDICINE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VASCULAR DISEASE; ANIMAL; CHEMISTRY; NANOMEDICINE; NEOPLASM;

ANIMALS; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85036451727     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2017.10.024     Document Type: Review

References (215)

1. Muntimadugu, E., Kommineni, N., Khan, W., Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy. Pharmacol. Res., 2017, 1–14, 10.1016/j.phrs.2017.05.010.
2. Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agents Smancs. Cancer Res. 46 (1986), 6387–6392, 10.1021/bc100070g.
3. Prabhakar, U., Maeda, H., Jain, R.K., Sevick-Muraca, E.M., Zamboni, W., Farokhzad, O.C., Barry, S.T., Gabizon, A., Grodzinski, P., Blakey, D.C., Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73 (2013), 2412–2417, 10.1158/0008-5472.CAN-12-4561.
4. Iyer, A.K., Khaled, G., Fang, J., Maeda, H., Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11 (2006), 812–818, 10.1016/j.drudis.2006.07.005.
5. Gabizon, A.A., Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52 (1992), 891–896.
6. Northfelt, D.W., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol., 16, 1998.
7. O'Brien, M.E.R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D.G., Tomczak, P., Ackland, S.P., Orlandi, F., Mellars, L., Alland, L., Tendler, C., Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX®/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15 (2004), 440–449, 10.1093/annonc/mdh097.
8. Harrington, K.J., Mohammadtaghi, S., Uster, P.S., Glass, D., Peters, a M., Vile, R.G., Stewart, J.S.W., Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 7 (2001), 243–254.
9. Hansen, A.E., Petersen, A.L., Henriksen, J.R., Boerresen, B., Rasmussen, P., Elema, D.R., Rosenschoeld, P.M., Kristensen, A.T., Kjær, A., Andresen, T.L., Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using Copper-64 liposomes. ACS Nano 9 (2015), 6985–6995, 10.1021/acsnano.5b01324.
10. Nichols, J.W., Bae, Y.H., Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 7 (2012), 606–618, 10.1016/j.nantod.2012.10.010.
11. Wilhelm, S., Tavares, A.J., Dai, Q., Ohta, S., Audet, J., Dvorak, H.F., Chan, W.C.W., Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater, 1, 2016, 16014, 10.1038/natrevmats.2016.14.
12. Minchinton, A.I., Tannock, I.F., Drug penetration in solid tumours. Nat. Rev. Cancer 6 (2006), 583–592, 10.1038/nrc1893.
13. El Emir, E., Qureshi, U., Dearling, J.L.J., Boxer, G.M., Clatworthy, I., Folarin, A.A., Robson, M.P., Nagl, S., Konerding, M.A., Pedley, R.B., Predicting Response to Radioimmunotherapy from the Tumor Microenvironment of Colorectal Carcinomas, vol. 67, 2007, 11896–11906, 10.1158/0008-5472.CAN-07-2967.
14. An, X., Zhu, A., Luo, H., Ke, H., Chen, H., Zhao, Y., Rational Design of Multi-stimuli-Responsive Nanoparticles for Precise Cancer Therapy. 2016, 10.1021/acsnano.6b01296.
15. Horsman, M.R., Vaupel, P., Pathophysiological basis for the formation of the tumor microenvironment. Front. Oncol., 6, 2016, 10.3389/fonc.2016.00066.
16. Egeblad, M., Nakasone, E.S., Werb, Z., Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell. 18 (2010), 884–901, 10.1016/j.devcel.2010.05.012.
17. Alizadeh, D., Zhang, L., Hwang, J., Schluep, T., Badie, B., Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas, Nanomedicine Nanotechnology. Biol. Med. 6 (2010), 382–390, 10.1016/j.nano.2009.10.001.
18. Miao, L., Liu, Q., Lin, C.M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W.Y., Huang, L., Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors. Cancer Res. 77 (2017), 719–731, 10.1158/0008-5472.CAN-16-0866.
19. Bhowmick, N.A., Neilson, E.G., Moses1, H.L., Stromal fibroblasts in cancer initiation and progression. Inflammation 432 (2011), 332–337, 10.1038/nature03096.Stromal.
20. Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel), 2015, 2443–2458, 10.3390/cancers7040902.
21. Nielsen, M.F.B., Mortensen, M.B., Detlefsen, S., Key players in pancreatic cancer-stroma interaction: cancer-associated fibroblasts, endothelial and inflammatory cells. World J. Gastroenterol. 22 (2016), 2678–2700, 10.3748/wjg.v22.i9.2678.
22. Fu, H., Yang, H., Zhang, X., Xu, W., The emerging roles of exosomes in tumor–stroma interaction. J. Cancer Res. Clin. Oncol. 142 (2016), 1897–1907, 10.1007/s00432-016-2145-0.
23. Alexander, J., Cukierman, E., Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions. Curr. Opin. Cell Biol. 42 (2016), 80–93, 10.1016/j.ceb.2016.05.002.
24. Hanley, C.J., Noble, F., Ward, M., Bullock, M., Drifka, C., Mellone, M., Manousopoulou, A., Johnston, H.E., Hayden, A., Thirdborough, S., Liu, Y., Smith, D.M., Mellows, T., Kao, W.J., Garbis, S.D., Mirnezami, A., Underwood, T.J., Eliceiri, K.W., Thomas, G.J., A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers. Oncotarget 7 (2015), 6159–6174, 10.18632/oncotarget.6740.
25. Paszek, M.J., Zahir, N., Johnson, K.R., Lakins, J.N., Rozenberg, G.I., Gefen, A., Reinhart-King, C.A., Margulies, S.S., Dembo, M., Boettiger, D., Hammer, D.A., Weaver, V.M., Tensional homeostasis and the malignant phenotype. Cancer Cell. 8 (2005), 241–254, 10.1016/j.ccr.2005.08.010.
26. Lu, P., Weaver, V.M., Werb, Z., The extracellular matrix: a dynamic niche in cancer progression. J. Cell. Biol. 196 (2012), 395–406, 10.1083/jcb.201102147.
27. Egeblad, M., Rasch, M.G., Weaver, V.M., Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell. Biol. 22 (2010), 697–706, 10.1016/j.ceb.2010.08.015.
28. Neesse, A., Michl, P., Frese, K.K., Feig, C., Cook, N., Jacobetz, M.A., Lolkema, M.P., Buchholz, M., Olive, K.P., Gress, T.M., Tuveson, D.A., Stromal biology and therapy in pancreatic cancer. Gut, 2011, 861–869, 10.1136/gut.2010.226092.
29. Levental, K.R., Yu, H., Kass, L., Lakins, J.N., Egeblad, M., Erler, J.T., Fong, S.F.T., Csiszar, K., Giaccia, A., Weninger, W., Yamauchi, M., Gasser, D.L., Weaver, V.M., Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139 (2009), 891–906, 10.1016/j.cell.2009.10.027.
30. Stylianopoulos, T., Martin, J.D., Chauhan, V.P., Jain, S.R., Diop-Frimpong, B., Bardeesy, N., Smith, B.L., Ferrone, C.R., Hornicek, F.J., Boucher, Y., Munn, L.L., Jain, R.K., Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 15101–15108, 10.1073/pnas.1213353109.
31. Hill, C., Jain, A., Takemoto, H., Silver, M.D., Nagesh, S.V.S., Ionita, C.N., Bednarek, D.R., Rudin, S., Effects of tumor microenvironment heterogeneity on nanoparticle disosition and efficacy in breast cancer tumor models. Proc. SPIE Int. Soc. Opt. Eng. 73 (2015), 389–400, 10.1530/ERC-14-0411.Persistent.
32. Netti, P.A., Berk, D.A., Swartz, M.A., Grodzinsky, A.J., Jain, R.K., Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60 (2000), 2497–2503, 10.1126/science.271.5252.1079.
33. Miao, L., Lin, C.M., Huang, L., Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J. Control. Release 219 (2015), 192–204, 10.1016/j.jconrel.2015.08.017.
34. Balkwill, F.R., Capasso, M., Hagemann, T., The tumor microenvironment at a glance. J. Cell. Sci. 125 (2012), 5591–5596, 10.1242/jcs.116392.
35. Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., Brossay, L., Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12 (2016), 239–252, 10.1038/nri3174.
36. Gregory, A.D., Houghton, A.M., Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 71 (2011), 2411–2416, 10.1158/0008-5472.CAN-10-2583.
37. Gardner, A., Ruffell, B., Dendritic cells and cancer immunity. Trends Immunol. 37 (2016), 855–865, 10.1016/j.it.2016.09.006.
38. Barnes, T.A., Amir, E., HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 117 (2017), 451–460, 10.1038/bjc.2017.220.
39. Hatziioannou, A., Alissafi, T., Verginis, P., Myeloid-derived suppressor cells and T regulatory cells in tumors : unraveling the dark side of the force. J. Leukoc. Biol. 102 (2017), 407–421, 10.1189/jlb.5VMR1116-493R.
40. Wittrup, K.D., Antitumor antibodies can drive therapeutic T cell responses. Trends Cancer xx (2017), 1–6, 10.1016/j.trecan.2017.07.001.
41. Min, Y., Roche, K.C., Tian, S., Eblan, M.J., McKinnon, K.P., Caster, J.M., Chai, S., Herring, L.E., Zhang, L., Zhang, T., DeSimone, J.M., Tepper, J.E., Vincent, B.G., Serody, J.S., Wang, A.Z., Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat. Nanotechnol., 2017, 10.1038/nnano.2017.113.
42. Stephan, M.T., Moon, J.J., Um, S.H., Bershteyn, A., Irvine, D.J., Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16 (2010), 1035–1041, 10.1038/nm.2198.
43. Boice, M., Salloum, D., Mourcin, F., Sanghvi, V., Amin, R., Oricchio, E., Jiang, M., Mottok, A., Denis-Lagache, N., Ciriello, G., Tam, W., Teruya-Feldstein, J., de Stanchina, E., Chan, W.C., Malek, S.N., Ennishi, D., Brentjens, R.J., Gascoyne, R.D., Cogné, M., Tarte, K., Wendel, H.G., Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-t cells. Cell, 167, 2016, 10.1016/j.cell.2016.08.032 405–418.e13.
44. Sarvaria, A., Madrigal, J.A., Saudemont, A., B cell regulation in cancer and anti-tumor immunity. Cell. Mol. Immunol. 14 (2017), 662–674, 10.1038/cmi.2017.35.
45. Schioppa, T., Moore, R., Thompson, R.G., Rosser, E.C., Kulbe, H., Nedospasov, S., Mauri, C., Coussens, L.M., Balkwill, F.R., B regulatory cells and the tumor-promoting actions of TNF- during squamous carcinogenesis. Proc. Natl. Acad. Sci. 108 (2011), 10662–10667, 10.1073/pnas.1100994108.
46. Andreu, P., Johansson, M., Affara, N.I., Pucci, F., Tan, T., Junankar, S., Korets, L., Lam, J., Tawfik, D., DeNardo, D.G., Naldini, L., de Visser, K.E., De Palma, M., Coussens, L.M., FcRγ activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell. 17 (2010), 121–134, 10.1016/j.ccr.2009.12.019.
47. Talmadge, J.E., Gabrilovich, D.I., Immunology, T.T., History of myeloid derived suppressor cells (MDSCs) in the macro- and micro-environment of tumour-bearing hosts. Nat. Rev. Cancer 13 (2015), 739–752, 10.1038/nrc3581.History.
48. Huang, B., Lei, Z., Zhao, J., Gong, W., Liu, J., Chen, Z., Liu, Y., Li, D., Yuan, Y., Zhang, G.M., Feng, Z.H., CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 252 (2007), 86–92, 10.1016/j.canlet.2006.12.012.
49. Lewis, C.E., Pollard, J.W., Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. Cancer Res. 66 (2006), 605–612, 10.1158/0008-5472.CAN-05-4005.
50. Zhang, Q., Liu, L., Gong, C., Shi, H., Zeng, Y., Wang, X., Prognostic Significance of Tumor-associated Macrophages in Solid Tumor: a Meta-analysis of the Literature, vol. 7, 2012, 10.1371/journal.pone.0050946.
51. Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C (High) Monocytes, vol. 70, 2010, 5728–5740, 10.1158/0008-5472.CAN-09-4672.
52. De Palma, M., Lewis, C.E., Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 23 (2013), 277–286, 10.1016/j.ccr.2013.02.013.
53. Laoui, D., Van Overmeire, E., Di Conza, G., Aldeni, C., Keirsse, J., Morias, Y., Tumor Hypoxia Does Not Drive Differentiation of Tumor-associated Macrophages but rather Fine-Tunes the M2-like Macrophage Population, vol. 74, 2014, 24–31, 10.1158/0008-5472.CAN-13-1196.
54. Silva, V.L., Al-jamal, W.T., Exploiting the cancer niche: tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy. J. Control. Release 253 (2017), 82–96, 10.1016/j.jconrel.2017.03.013.
55. Carmona-Fontaine, C., Deforet, M., Akkari, L., Thompson, C.B., Joyce, J.A., Xavier, J.B., Metabolic origins of spatial organization in the tumor microenvironment. Proc. Natl. Acad. Sci. 114 (2017), 2934–2939, 10.1073/pnas.1700600114.
56. Miller, M.A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R.H., Iwamoto, Y., Yang, K.S., Askevold, B., Kolishetti, N., Pittet, M., Lippard, S.J., Farokhzad, O.C., Weissleder, R., Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat. Commun., 6, 2015, 8692, 10.1038/ncomms9692.
57. Cuccarese, M.F., Dubach, J.M., Pfirschke, C., Engblom, C., Garris, C., Miller, M.A., Pittet, M.J., Weissleder, R., Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma. Nat. Commun. 8 (2017), 1–10, 10.1038/ncomms14293.
58. Vaupel, P., Pathophysiological and vascular characteristics of solid tumors in relation to drug delivery. Drug Deliv. Oncol. From Basic Res. To Cancer Ther., 2012.
59. Jain, R.K., Molecular regulation of vessel maturation. Nat. Med. 9 (2003), 685–693, 10.1038/nm0603-685.
60. Azzi, S., Hebda, J.K., Gavard, J., Vascular permeability and drug delivery in cancers. Front. Oncol. 3 (2013), 1–14, 10.3389/fonc.2013.00211.
61. Barlow, K.D., Sanders, A.M., Soker, S., Ergun, S., Metheny-barlow, L.J., Pericytes on the tumor vasculature: Jekyll or Hyde ?. Cancer Microenviron., 2013, 1–17, 10.1007/s12307-012-0102-2.
62. Hashizume, H., Baluk, P., Morikawa, S., McLean, J.W., Thurston, G., Roberge, S., Jain, R.K., McDonald, D.M., Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156 (2000), 1363–1380, 10.1016/S0002-9440(10)65006-7.
63. Hellström, M., Gerhardt, H., Kalén, M., Li, X., Eriksson, U., Wolburg, H., Betsholtz, C., Lack of Pericytes Leads to Endothelial Hyperplasia and Abnormal Vascular Morphogenesis, vol. 153, 2001, 543–553.
64. Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R.K., McDonald, D.M., Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160 (2002), 985–1000, 10.1016/S0002-9440(10)64920-6.
65. Baluk, P., Hashizume, H., M, D.M., Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15 (2005), 102–111, 10.1016/j.gde.2004.12.005.
66. Wang, M., Zhao, X., Zhu, D., Liu, T., Liang, X., Liu, F., Zhang, Y., HIF-1 Α Promoted Vasculogenic Mimicry Formation in Hepatocellular Carcinoma through LOXL2 Up-regulation in Hypoxic Tumor Microenvironment. 2017, 1–14, 10.1186/s13046-017-0533-1.
67. Jain, R.K., Transport of Molecules in the Tumor Interstitium: a Review, vol. 500, 1987, 3039–3052.
68. Heldin, C.-H., Rubin, K., Pietras, K., Ostman, A., High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4 (2004), 806–813, 10.1038/nrc1456.
69. Jain, R.K., Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6 (1987), 559–593, 10.1007/BF00047468.
70. Matsumoto, Y., Nichols, J.W., Toh, K., Nomoto, T., Cabral, H., Miura, Y., Christie, R.J., Yamada, N., Ogura, T., Kano, M.R., Matsumura, Y., Nishiyama, N., Yamasoba, T., Bae, Y.H., Kataoka, K., Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat. Nanotechnol. 11 (2016), 533–538, 10.1038/nnano.2015.342.
71. Fukumura, D., Duda, D.G., Munn, L.L., Jain, R.K., Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17 (2010), 206–225, 10.1111/j.1549-8719.2010.00029.x.
72. Leunig, M., Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res. 52 (1992), 6553–6560.
73. Fukumura, D., Jain, R.K., Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 74 (2007), 72–84, 10.1016/j.mvr.2007.05.003.
74. Baxter, L.T., Jain, R.K., Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc. Res. 37 (1989), 77–104, 10.1016/0026-2862(89)90074-5.
75. Tong, R.T., Boucher, Y., Kozin, S.V., Winkler, F., Hicklin, D.J., Jain, R.K., Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004), 3731–3736, 10.1158/0008-5472.CAN-04-0074.
76. Stylianopoulos, T., Martin, J.D., Snuderl, M., Mpekris, F., Jain, S.R., Jain, R.K., Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res. 73 (2013), 3833–3841, 10.1158/0008-5472.CAN-12-4521.
77. Padera, T.P., Stoll, B.R., Tooredman, J.B., Capen, D., di Tomaso, E., Jain, R.K., Pathology: cancer cells compress intratumour vessels. Nature, 427, 2004, 695, 10.1038/427695a.
78. Heine, M., Freund, B., Nielsen, P., Jung, C., Reimer, R., High Interstitial Fluid Pressure Is Associated with Low Tumour Penetration of Diagnostic Monoclonal Antibodies Applied for Molecular Imaging Purposes, vol. 7, 2012, 10.1371/journal.pone.0036258.
79. Stapleton, S., Milosevic, M., Tannock, I.F., Allen, C., Jaffray, D.A., The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation. J. Control. Release 211 (2015), 163–170, 10.1016/j.jconrel.2015.06.008.
80. Mayers, J.R., Vander Heiden, M.G., Nature and Nurture: what Determines tumor metabolic phenotypes?. Cancer Res., 2017, 3131–3135, 10.1158/0008-5472.CAN-17-0165.
81. Manuscript, A., Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 31 (2013), 522–529, 10.1038/nbt.2530.Heterogeneity.
82. Hockl, P.F., Wolosiuk, A., Perez-Saez, J.M., Bordoni, A.V., Croci, D.O., Toum-Terrones, Y., Soler-Illia, G.J.A.A., Rabinovich, G.A., Glyco-nano-oncology: novel therapeutic opportunities by combining small and sweet. Pharmacol. Res. 109 (2016), 45–54, 10.1016/j.phrs.2016.02.005.
83. Zeng, W., Liu, P., Pan, W., Ram, S., Wei, Y., Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 356 (2015), 263–267, 10.1016/j.canlet.2014.01.032.
84. Fokas, E., McKenna, W.G., Muschel, R.J., The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. Cancer Metastasis Rev. 31 (2012), 823–842, 10.1007/s10555-012-9394-4.
85. Michiels, C., Tellier, C., Feron, O., Cycling hypoxia: a key feature of the tumor microenvironment. BBA Rev. Cancer 1866 (2016), 76–86, 10.1016/j.bbcan.2016.06.004.
86. Milosevic, M., Fyles, A., Hedley, D., Hill, R., The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin. Radiat. Oncol. 14 (2004), 249–258, 10.1016/j.semradonc.2004.04.006.
87. Reina-Campos, M., Moscat, J., Diaz-Meco, M., Metabolism shapes the tumor microenvironment. Curr. Opin. Cell. Biol. 48 (2017), 47–53, 10.1016/j.ceb.2017.05.006.
88. G. Helmlinger, F. Yuan, M. Dellian, R.K. Jain, Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation, Nature. (n.d.).
89. Wojtkowiak, J.W., Verduzco, D., Schramm, K.J., Gillies, R.J., Drug Resistance and Cellular Adaptation to Tumor Acidic PH Microenvironment. 2011, 2032–2038.
90. Ding, C., Tong, L., Feng, J., Fu, J., Recent advances in stimuli-responsive release function drug delivery systems for tumor treatment. Molecules, 21, 2016, 10.3390/molecules21121715.
91. Hakomori, S., Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 10231–10233, 10.1073/pnas.172380699.
92. Chan, C.W., Perrault, S.D., Walkey, C., Jennings, T., Fischer, H.C., Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9 (2009), 1909–1915, 10.1021/nl900031y.
93. Walkey, C.D., Olsen, J.B., Song, F., Liu, R., Guo, H., Olsen, D.W.H., Cohen, Y., Emili, A., Chan, W.C.W., Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8 (2014), 2439–2455, 10.1021/nn406018q.
94. Ernsting, M.J., Murakami, M., Roy, A., Li, S.D., Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Control. Release 172 (2013), 782–794, 10.1016/j.jconrel.2013.09.013.
95. Florence, A.T., “Targeting” nanoparticles: the constraints of physical laws and physical barriers. J. Control. Release 164 (2012), 115–124, 10.1016/j.jconrel.2012.03.022.
96. Liu, J., Yu, M., Zhou, C., Zheng, J., Renal clearable inorganic nanoparticles : a new frontier of bionanotechnology. Biochem. Pharmacol. 16 (2013), 477–486, 10.1016/j.mattod.2013.11.003.
97. Albanese, A., Tang, P.S., Chan, W.C.W., The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14 (2012), 1–16, 10.1146/annurev-bioeng-071811-150124.
98. Dreher, M.R., Liu, W., Michelich, C.R., Dewhirst, M.W., Yuan, F., Chilkoti, A., Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers. 2006, 335–344, 10.1093/jnci/djj070.
99. Lee, H., Fonge, H., Hoang, B., Reilly, R.M., Allen, C., The Effects of Particle Size and Molecular Targeting on the Intratumoral and Subcellular Distribution of Polymeric Nanoparticles, vol. 7, 2010, 1195–1208.
100. Sykes, E.A., Chen, J., Zheng, G., Chen, W., Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency. 2014, 5696–5706.
101. Ruan, S., Cao, X., Cun, X., Hu, G., Zhou, Y., Zhang, Y., Lu, L., He, Q., Gao, H., Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release. Biomaterials 60 (2015), 100–110, 10.1016/j.biomaterials.2015.05.006.
102. Zhang, P., Wang, C., Zhao, J., Xiao, A., Shen, Q., Li, L., Li, J., Zhang, J., Min, Q., Chen, J., Chen, H., Zhu, J., Near Infrared-guided Smart Nanocarriers for MicroRNA-controlled Release of Doxorubicin/SiRNA with Intracellular ATP as Fuel. 2016, 10.1021/acsnano.5b08145.
103. Chithrani, B.D., Chan, W.C.W., Elucidating the Mechanism of Cellular Uptake and Removal of Protein-coated Gold Nanoparticles of Different Sizes and Shapes. 2007.
104. Truong, N.P., Whittaker, M.R., Mak, C.W., Davis, T.P., The Importance of Nanoparticle Shape in Cancer Drug Delivery, vol. 5247, 2017, 10.1517/17425247.2014.950564.
105. Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T., Discher, D.E., Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2 (2007), 249–255, 10.1038/nnano.2007.70.
106. V Jokerst, J., Lobovkina, T., Zare, R.N., Gambhir, S.S., Nanoparticle PEGylation for imaging and therapy. Nanomed. (Lond) 6 (2011), 715–728, 10.2217/nnm.11.19.
107. Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Injection of PEGylated Liposomes in Rats Elicits PEG-specific IgM, Which Is Responsible for Rapid Elimination of a Second Dose of PEGylated Liposomes, vol. 112, 2006, 15–25, 10.1016/j.jconrel.2006.01.005.
108. Ishihara, T., Takeda, M., Sakamoto, H., Kimoto, A., Kobayashi, C., Takasaki, N., Yuki, K., Tanaka, K., Takenaga, M., Igarashi, R., Maeda, T., Yamakawa, N., Okamoto, Y., Otsuka, M., Ishida, T., Kiwada, H., Mizushima, Y., Mizushima, T., Accelerated Blood Clearance Phenomenon upon Repeated Injection of PEG-modified PLA-nanoparticles, vol. 26, 2009, 2270–2279, 10.1007/s11095-009-9943-x.
109. Moghimi, S.M., Andersen, A.J., Hashemi, S.H., Lettiero, B., Ahmadvand, D., Hunter, A.C., Andresen, T.L., Hamad, I., Szebeni, J., Complement activation cascade triggered by PEG – PL engineered nanomedicines and carbon nanotubes : the challenges ahead. J. Control. Release 146 (2010), 175–181, 10.1016/j.jconrel.2010.04.003.
110. Knop, K., Hoogenboom, R., Fischer, D., Schubert, U.S., Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. - Int. Ed. 49 (2010), 6288–6308, 10.1002/anie.200902672.
111. Liu, S., Jiang, S., Chemical conjugation of zwitterionic polymers protects immunogenic enzyme and preserves bioactivity without polymer-specific antibody response. Nano Today 11 (2016), 285–291, 10.1016/j.nantod.2016.05.006.
112. Luk, B.T., Zhang, L., Cell membrane-camouflaged nanoparticles for drug delivery. J. Control. Release 220 (2015), 600–607, 10.1016/j.jconrel.2015.07.019.
113. Hu, C.J., Zhang, L., Aryal, S., Cheung, C., Fang, R.H., Zhang, L., Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 10980–10985, 10.1073/pnas.1106634108.
114. Rao, L., Bu, L.L., Xu, J.H., Cai, B., Yu, G.T., Yu, X., He, Z., Huang, Q., Li, A., Guo, S.S., Zhang, W.F., Liu, W., Sun, Z.J., Wang, H., Wang, T.H., Zhao, X.Z., Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small 11 (2015), 6225–6236, 10.1002/smll.201502388.
115. Rao, L., Meng, Q.F., Bu, L.L., Cai, B., Huang, Q., Sun, Z.J., Zhang, W.F., Li, A., Guo, S.S., Liu, W., Wang, T.H., Zhao, X.Z., Erythrocyte membrane-coated upconversion nanoparticles with minimal protein adsorption for enhanced tumor imaging. ACS Appl. Mat. Interfaces 9 (2017), 2159–2168, 10.1021/acsami.6b14450.
116. Fang, R.H., Hu, C.M.J., Luk, B.T., Gao, W.W., Copp, J.A., Tai, Y.Y., O'Connor, D.E., Zhang, L.F., Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 14 (2014), 2181–2188.
117. Rao, L., Bu, L.L., Meng, Q.F., Cai, B., Deng, W.W., Li, A., Li, K., Guo, S.S., Zhang, W.F., Liu, W., Sun, Z.J., Zhao, X.Z., Antitumor platelet-mimicking magnetic nanoparticles. Adv. Funct. Mater, 27, 2017, 10.1002/adfm.201604774.
118. Hu, C.J., Fang, R.H., Wang, K., Luk, B.T., Thamphiwatana, S., Dehaini, D., Nguyen, P., Angsantikul, P., Wen, C.H., V Kroll, A., Carpenter, C., Ramesh, M., Qu, V., Patel, S.H., Zhu, J., Shi, W., Hofman, F.M., Chen, T.C., Gao, W., Zhang, K., Chien, S., Zhang, L., Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526 (2015), 118–121, 10.1038/nature15373.
119. Kang, T., Zhu, Q., Wei, D., Feng, J., Yao, J., Jiang, T., Song, Q., Wei, X., Chen, H., Gao, X., Chen, J., Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis. ACS Nano 11 (2017), 1397–1411, 10.1021/acsnano.6b06477.
120. Teng, L., Xie, J., Teng, L., Lee, R.J., Clinical translation of folate receptor-targeted therapeutics. Expert Opin. Drug Deliv. 9 (2012), 901–908, 10.1517/17425247.2012.694863.
121. Bergamini, A., Ferrero, S., Leone Roberti Maggiore, U., Scala, C., Pella, F., Vellone, V.G., Petrone, M., Rabaiotti, E., Cioffi, R., Candiani, M., Mangili, G., Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. Expert Opin. Investig. Drugs 25 (2016), 1405–1412, 10.1080/13543784.2016.1254616.
122. Cheng, J., Teply, B.A., Sherifi, I., Sung, J., Luther, G., Gu, F.X., Levy-Nissenbaum, E., Radovic-Moreno, A.F., Langer, R., Farokhzad, O.C., Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28 (2007), 869–876, 10.1016/j.biomaterials.2006.09.047.
123. Xiang, B., Dong, D.W., Shi, N.Q., Gao, W., Yang, Z.Z., Cui, Y., Cao, D.Y., Qi, X.R., PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials 34 (2013), 6976–6991, 10.1016/j.biomaterials.2013.05.055.
124. Lammers, T., Kiessling, F., Hennink, W.E., Storm, G., Drug targeting to tumors : principles, pitfalls and (pre-) clinical progress. J. Control. Release 161 (2012), 175–187, 10.1016/j.jconrel.2011.09.063.
125. Chauhan, V.P., Stylianopoulos, T., Boucher, Y., Jain, R.K., Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2 (2011), 281–298, 10.1146/annurev-chembioeng-061010-114300.
126. Holback, H., Yeo, Y., Intratumoral drug delivery with nanoparticulate carriers. Pharm. Res. 28 (2011), 1819–1830, 10.1007/s11095-010-0360-y.
127. Sykes, E.A., Dai, Q., Sarsons, C.D., Chen, J., Rocheleau, J.V., Hwang, D.M., Zheng, G., Cramb, D.T., Rinker, K.D., Chan, W.C.W., Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc. Natl. Acad. Sci., 2016, 201521265, 10.1073/pnas.1521265113.
128. Rosenberger, I., Strauss, A., Dobiasch, S., Weis, C., Szanyi, S., Gil-Iceta, L., Alonso, E., González Esparza, M., Gómez-Vallejo, V., Szczupak, B., Plaza-García, S., Mirzaei, S., Israel, L.L., Bianchessi, S., Scanziani, E., Lellouche, J.P., Knoll, P., Werner, J., Felix, K., Grenacher, L., Reese, T., Kreuter, J., Jiménez-González, M., Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. J. Control. Release 214 (2015), 76–84, 10.1016/j.jconrel.2015.07.017.
129. Murphy, E.A., Majeti, B.K., Barnes, L.A., Makale, M., Weis, S.M., Lutu-Fuga, K., Wrasidlo, W., Cheresh, D.A., Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 9343–9348, 10.1073/pnas.0803728105.
130. Wang, J., Lee, G.Y., Lu, Q., Peng, X., Wu, J., Wu, S., Kairdolf, B.A., Nie, S., Wang, Y., Lane, L.A., Quantitative examination of the active targeting effect: the key factor for maximal tumor accumulation and retention of short-circulated biopolymeric nanocarriers. Bioconjug. Chem., 2017, 10.1021/acs.bioconjchem.7b00138.
131. Dai, Y., Xu, C., Chen, X., Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem. Soc. Rev., 2017, 10.1039/C6CS00592F.
132. Kanamala, M., Wilson, W.R., Yang, M., Palmer, B.D., Wu, Z., Mechanisms and biomaterials in pH-responsive tumor targeted drug delivery: a review Manju. Biomaterials, 2016, 10.1016/j.biomaterials.2016.01.061.
133. Li, H.J., Du, J.Z., Liu, J., Du, X.J., Shen, S., Zhu, Y.H., Wang, X., Ye, X., Nie, S., Wang, J., Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration. ACS Nano 10 (2016), 6753–6761, 10.1021/acsnano.6b02326.
134. Li, H., Du, J., Du, X., Xu, C., Sun, C., Wang, H., Cao, Z., Stimuli-responsive Clustered Nanoparticles for Improved Tumor Penetration and Therapeutic Efficacy. 2016, 6–11, 10.1073/pnas.1522080113.
135. Lu, N., Huang, P., Fan, W., Wang, Z., Liu, Y., Wang, S., Zhang, G., Hu, J., Liu, W., Niu, G., Leapman, R.D., Lu, G., Chen, X., Tri-stimuli-responsive biodegradable theranostics for mild hyperthermia enhanced chemotherapy. Biomaterials 126 (2017), 39–48, 10.1016/j.biomaterials.2017.02.025.
136. Perche, F., Biswas, S., Wang, T., Zhu, L., Torchilin, V., Hypoxia-targeted siRNA delivery. Angew. Chem. - Int. Ed. 53 (2015), 3362–3366, 10.1002/anie.201308368.Hypoxia-targeted.
137. Qian, C., Yu, J., Chen, Y., Hu, Q., Xiao, X., Sun, W., Light-activated Hypoxia-responsive Nanocarriers for Enhanced Anticancer Therapy. 2016, 3313–3320, 10.1002/adma.201505869.
138. Karimi, M., Sahandi Zangabad, P., Baghaee-Ravari, S., Ghazadeh, M., Mirshekari, H., Hamblin, M.R., Smart nanostructures for cargo delivery: uncaging and activating by light. J. Am. Chem. Soc. 139 (2017), 4584–4610, 10.1021/jacs.6b08313.
139. Luo, D., Carter, K.A., Razi, A., Geng, J., Shao, S., Giraldo, D., Sunar, U., Ortega, J., Lovell, J.F., Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release. Biomaterials 75 (2016), 193–202, 10.1016/j.biomaterials.2015.10.027.
140. May, J.P., Li, S.-D., Hyperthermia-induced drug targeting. Expert Opin. Drug Deliv. 10 (2013), 511–527, 10.1517/17425247.2013.758631.
141. Needham, D., Anyarambhatla, G., Kong, G., A New Temperature-sensitive Liposome for Use with Mild Hyperthermia : Characterization and Testing in a Human Tumor Xenograft Model Advances in Brief a New Temperature-sensitive Liposome for Use with Mild Hyperthermia : Characterization and Testing in a H. 2000, 1197–1201.
142. Li, Z., Ye, E., Lakshminarayanan, R., Loh, X.J., Recent Advances of Using Hybrid Nanocarriers in Remotely Controlled Therapeutic Delivery. 2016, 4782–4806, 10.1002/smll.201601129.
143. Gasselhuber, A., Dreher, M.R., Rattay, F., Wood, B.J., Haemmerich, D., Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model. PLoS One, 7, 2012, 10.1371/journal.pone.0047453.
144. Lencioni, R., Cioni, D., RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. Hepatic Oncol. 3 (2016), 193–200, 10.2217/hep-2016-0005.
145. Dong, X., Wei, C., Liang, J., Liu, T., Kong, D., Lv, F., Thermosensitive hydrogel loaded with chitosan-carbon nanotubes for near infrared light triggered drug delivery. Colloids Surf. B Biointerfaces 154 (2017), 253–262, 10.1016/j.colsurfb.2017.03.036.
146. Rahoui, N., Jiang, B., Taloub, N., Huang, Y.D., Spatio-temporal control strategy of drug delivery systems based nano structures. J. Control. Release 255 (2017), 176–201, 10.1016/j.jconrel.2017.04.003.
147. Eisenbrey, J.R., Soulen, M.C., Wheatley, M.A., Delivery of Encapsulated Doxorubicin by Ultrasound-mediated Size Reduction of Drug-loaded Polymer Contrast Agents. vol. 57, 2010, 24–28.
148. Paproski, R.J., Forbrich, A., Huynh, E., Chen, J., Lewis, J.D., Zheng, G., Zemp, R.J., Porphyrin nanodroplets: sub-micrometer ultrasound and photoacoustic contrast imaging agents. Small 12 (2016), 371–380, 10.1002/smll.201502450.
149. Rizzitelli, S., Giustetto, P., Cutrin, J.C., Castelli, D.D., Boffa, C., Ruzza, M., Menchise, V., Molinari, F., Aime, S., Terreno, E., Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound. J. Control. Release 202 (2015), 21–30, 10.1016/j.jconrel.2015.01.028.
150. Rizzitelli, S., Giustetto, P., Faletto, D., Castelli, D.D., Aime, S., Terreno, E., The release of Doxorubicin from liposomes monitored by MRI and triggered by a combination of US stimuli led to a complete tumor regression in a breast cancer mouse model. J. Control. Release, 2016, 10.1016/j.jconrel.2016.03.040.
151. Huynh, E., Lowell, J.F., Helfield, B.L., Jeon, M., Kim, C., Goertz, D.E., Wilson, B.C., Zheng, G., Porphyrin Shell Microbubbles with Intrinsic Ultrasound and Photoacoustic Properties. 2012.
152. Huynh, E., Leung, B.Y.C., Hel, B.L., Shakiba, M., Gandier, J., Jin, C.S., Master, E.R., Wilson, B.C., Goertz, D.E., Zheng, G., In Situ Conversion of Porphyrin Microbubbles to Nanoparticles for Multimodality Imaging. 2015, 1–8, 10.1038/nnano.2015.25.
153. Huynh, E., Zheng, G., Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Nanomedicine, 2015, 15–17, 10.2217/nnm.15.86.
154. Perrault, S.D., Chan, W.C.W., In vivo assembly of nanoparticle components to improve targeted cancer imaging. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 11194–11199, 10.1073/pnas.1001367107.
155. Ye, D., Shuhendler, A.J., Cui, L., Tong, L., Tee, S.S., Tikhomirov, G., Felsher, D.W., Rao, J., Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo. Nat. Chem. 6 (2014), 519–526, 10.1038/nchem.1920.
156. Hu, Q., Sun, W., Lu, Y., Bomba, H.N., Ye, Y., Jiang, T., Isaacson, A.J., Gu, Z., Tumor microenvironment-mediated construction and deconstruction of extracellular drug-delivery depots. Nano Lett. 16 (2016), 1118–1126, 10.1021/acs.nanolett.5b04343.
157. Shrivastava, R., Bhadauria, S., Chourasia, M.K., Targeting tumor associated macrophages (TAMs) via nanocarriers. J. Control. Release 254 (2017), 92–106, 10.1016/j.jconrel.2017.03.395.
158. Choi, M.R., Stanton-Maxey, K.J., Stanley, J.K., Levin, C.S., Bardhan, R., Akin, D., Badve, S., Sturgis, J., Robinson, J.P., Bashir, R., Halas, N.J., Clare, S.E., A cellular trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 7 (2007), 3759–3765, 10.1021/nl072209h.
159. Choi, M.-R., Bardhan, R., Stanton-Maxey, K.J., Badve, S., Nakshatri, H., Stantz, K.M., Cao, N., Halas, N.J., Clare, S.E., Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnol. 3 (2012), 47–54, 10.1007/s12645-012-0029-9.
160. Smith, B.R., Ghosn, E.E.B., Rallapalli, H., Prescher, J.A., Larson, T., Herzenberg, L.A., Gambhir, S.S., Selective uptake of single-walled carbon nanotubes by circulating monocytes for enhanced tumour delivery. Nat. Nanotechnol. 9 (2014), 481–487, 10.1038/nnano.2014.62.
161. Xue, J., Zhao, Z., Zhang, L., Xue, L., Shen, S., Wen, Y., Wei, Z., Wang, L., Kong, L., Sun, H., Ping, Q., Mo, R., Zhang, C., Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat. Nanotechnol. 12 (2017), 692–700, 10.1038/nnano.2017.54.
162. Stapleton, S., Jaffray, D., Milosevic, M., Radiation effects on the tumor microenvironment: implications for nanomedicine delivery. Adv. Drug Deliv. Rev., 2016, 10.1016/j.addr.2016.05.021.
163. Davies, C.D.L., Lundstrom, L.M., Frengen, J., Eikenes, L., Bruland, O.S., Kaalhus, O., Hjelstuen, M.H.B., Brekken, C., Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res. 64 (2004), 547–553, 10.1158/0008-5472.CAN-03-0576.
164. Li, C., Ke, S., Wu, Q., Tansey, W., Hunter, N., Buchmiller, L.M., Milas, L., Charnsangavej, C., Wallace, S., Tumor irradiation enhances the tumor-specific distribution of poly(l-glutamic acid) -conjugated paclitaxel and its antitumor efficacy. Clin. Cancer Res. 6 (2000), 2829–2834.
165. Giustini, A.J., Petryk, A.A., Hoopes, P.J., Ionizing radiation increases systemic nanoparticle tumor accumulation. Nanomed. Nanotechnol. Biol. Med. 8 (2012), 818–821, 10.1016/j.nano.2012.05.001.
166. Zhang, L., Li, R., Chen, H., Wei, J., Qian, H., Su, S., Shao, J., Wang, L., Qian, X., Liu, B., Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer. Int. J. Nanomed. 12 (2017), 2129–2142, 10.2147/IJN.S126016.
167. Lammers, T., Peschke, P., Kuhnlein, R., Subr, V., Ulbrich, K., Debus, J., Huber, P., Hennink, W., Storm, G., Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J. Control. Release 117 (2007), 333–341, 10.1016/j.jconrel.2006.10.032.
168. Park, J.S., Qiao, L., Su, Z.Z., Hinman, D., Willoughby, K., McKinstry, R., Yacoub, A., Duigou, G.J., Young, C.S.H., Grant, S., Hagan, M.P., Elliss, E., Fisher, P.B., Dent, P., Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways (vol. 20, pg 3266, 2001). Oncogene, 20, 2001, 7817, 10.1038/Sj.Onc.1204931.
169. Garcia-barros, M., Lyden, D., Rafii, S., Haimovitz-friedman, A., Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis, vol. 1155, 2014, 10.1126/science.1082504.
170. Potiron, V.A., Abderrahmani, R., Clement-Colmou, K., Marionneau-Lambot, S., Oullier, T., Paris, F., Supiot, S., Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer. PLoS One, 8, 2013, 10.1371/journal.pone.0084076.
171. Znati, C.A., Rosenstein, M., Boucher, Y., Epperly, M.W., Bloomer, W.D., Jain, R.K., Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res. 56 (1996), 964–968.
172. Miller, M.A., Chandra, R., Cuccarese, M.F., Pfirschke, C., Engblom, C., Stapleton, S., Adhikary, U., Kohler, R.H., Mohan, J.F., Pittet, M.J., Weissleder, R., Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci. Transl. Med., 9, 2017, 10.1126/scitranslmed.aal0225 eaal0225.
173. Fukumura, D., Jain, R.K., Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 101 (2007), 937–949, 10.1002/jcb.21187.
174. Durymanov, M.O., Rosenkranz, A.A., Sobolev, A.S., Current approaches for improving intratumoral accumulation and distribution of nanomedicines. Theranostics 5 (2015), 1007–1020, 10.7150/thno.11742.
175. Kirui, D.K., Celia, C., Molinaro, R., Bansal, S.S., Cosco, D., Mild Hyperthermia Enhances Transport of Liposomal Gemcitabine and Improves in Vivo Therapeutic Response. 2015, 1092–1103, 10.1002/adhm.201400738.
176. Bagley, A.F., Scherz-shouval, R., Galie, P.A., Zhang, A.Q., Wyckoff, J., Whitesell, L., Chen, C.S., Lindquist, S., Endothelial Thermotolerance Impairs Nanoparticle Transport in Tumors. 2015, 3255–3268, 10.1158/0008-5472.CAN-15-0325.
177. Park, J.-H., von Maltzahn, G., Xu, M.J., Fogal, V., Kotamraju, V.R., Ruoslahti, E., Bhatia, S.N., Sailor, M.J., Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 981–986, 10.1073/pnas.0909565107.
178. Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ph, D., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., Kabbinavar, F., Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. 2004, 2335–2342.
179. Stylianopoulos, T., Jain, R.K., Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 18632–18637, 10.1073/pnas.1318415110.
180. Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Sci. (80-.) 307 (2005), 58–62, 10.1126/science.1104819.
181. Chauhan, V.P., Stylianopoulos, T., Martin, J.D., Popović, Z., Chen, O., Kamoun, W.S., Bawendi, M.G., Fukumura, D., Jain, R.K., Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7 (2012), 383–388, 10.1038/nnano.2012.45.
182. Luan, X., Guan, Y.Y., Lovell, J.F., Zhao, M., Lu, Q., Liu, Y.R., Liu, H.J., Gao, Y.G., Dong, X., Yang, S.C., Zheng, L., Sun, P., Fang, C., Chen, H.Z., Tumor priming using metronomic chemotherapy with neovasculature-targeted, Nanoparticulate paclitaxel. Biomaterials 95 (2016), 60–73, 10.1016/j.biomaterials.2016.04.008.
183. Li, S., Zhang, Y., Wang, J., Zhao, Y., Ji, T., Zhao, X., Ding, Y., Zhao, X., Zhao, R., Li, F., Yang, X., Liu, S., Liu, Z., Lai, J., Whittaker, A.K., Anderson, G.J., Wei, J., Nie, G., Nanoparticle-mediated local depletion of tumour- associated platelets disrupts vascular barriers and augments drug accumulation in tumours. Nat. Biomed. Eng., 1, 2017, 10.1038/s41551-017-0115-8.
184. Grantab, R., Sivananthan, S., Tannock, I.F., The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res. 66 (2006), 1033–1039, 10.1158/0008-5472.CAN-05-3077.
185. Wang, J., Lu, Z., Gao, Y., Wientjes, M.G., Au, J.L.-S., Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomedicine 6 (2011), 1605–1620, 10.2217/nnm.11.141.
186. Jang, S.H., Wientjes, M.G., Au, J.L., Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J. Pharmacol. Exp. Ther. 296 (2001), 1035–1042.
187. Lu, D., Wientjes, M.G., Lu, Z., Au, J.L.-S., Tumor priming enhances delivery and efficacy of nanomedicines. J. Pharmacol. Exp. Ther. 322 (2007), 80–88, 10.1124/jpet.107.121632.
188. Danhier, F., Danhier, P., De Saedeleer, C.J., Fruytier, A.C., Schleich, N., Des Rieux, A., Sonveaux, P., Gallez, B., Préat, V., Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors. Int. J. Pharm. 479 (2015), 399–407, 10.1016/j.ijpharm.2015.01.009.
189. Geretti, E., Leonard, S.C., Dumont, N., Lee, H., Zheng, J., De Souza, R., Gaddy, D.F., Espelin, C.W., Jaffray, D. a, Moyo, V., Nielsen, U.B., Wickham, T.J., Hendriks, B.S., Cyclophosphamide-mediated tumor priming for enhanced delivery and antitumor activity of HER2-targeted liposomal doxorubicin (MM-302). Mol. Cancer Ther. 14 (2015), 2060–2071, 10.1158/1535-7163.MCT-15-0314.
190. Goins, B., Phillips, W.T., Bao, A., Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy. Expert Opin. Drug Deliv. 13 (2016), 873–889, 10.1517/17425247.2016.1167035.
191. Choi, J., Credit, K., Henderson, K., Deverkadra, R., He, Z., Wiig, H., Vanpelt, H., Flessner, M.F., Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration. Clin. Cancer Res. 12 (2006), 1906–1912, 10.1158/1078-0432.CCR-05-2141.
192. Eikenes, L., Tari, M., Tufto, I., Bruland, O.S., de Lange Davies, C., Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 93 (2005), 81–88, 10.1038/sj.bjc.6602626.
193. Gong, H., Chao, Y., Xiang, J., Han, X., Song, G., Hyaluronidase to enhance nanoparticle-based photodynamic tumor therapy hyaluronidase to enhance nanoparticle-based photodynamic tumor therapy. Nano Lett., 2016, 10.1021/acs.nanolett.6b00068.
194. Provenzano, P.P., Cuevas, C., Chang, A.E., Goel, V.K., Von Hoff, D.D., Hingorani, S.R., Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 21 (2012), 418–429, 10.1016/j.ccr.2012.01.007.
195. Murty, S., Gilliland, T., Qiao, P., Tabtieng, T., Higbee, E., Al Zaki, A., Pure, E., Tsourkas, A., Nanoparticles functionalized with collagenase exhibit improved tumor accumulation in a murine xenograft model. Part. Part. Syst. Charact. 31 (2014), 1307–1312, 10.1002/ppsc.201400169.
196. Zhou, H., Fan, Z., Deng, J., Lemons, P.K., Arhontoulis, D.C., Bowne, W.B., Cheng, H., Hyaluronidase Embedded in Nanocarrier PEG Shell for Enhanced Tumor Penetration and Highly E Ffi Cient Antitumor Efficacy. 2016, 10.1021/acs.nanolett.6b00820.
197. Agostinis, P., Berg, K., Cengel, K. a, Foster, T.H., Girotti, A.W., Gollnick, S.O., Hahn, S.M., Hamblin, M.R., Juzeniene, A., Kessel, D., Korbelik, M., Moan, J., Mroz, P., Nowiz, D., Piette, J., Willson, B.C., Golab, J., Photodynamic therapy of cancer: an update. Am. Cancer Soc. 61 (2011), 250–281, 10.3322/caac.20114.Available.
198. Wilson, B.C., Patterson, M.S., The physics, biophysics and technology of photodynamic therapy. Phys. Med. Biol. 53 (2008), R61–R109, 10.1088/0031-9155/53/9/R01.
199. Alyssa, S.G., Mastera; megan, livingstona; anirban, photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges. J. Control Release 29 (2012), 997–1003, 10.1016/j.biotechadv.2011.08.021.Secreted.
200. Madar-Balakirski, N., Tempel-Brami, C., Kalchenko, V., Brenner, O., Varon, D., Scherz, A., Salomon, Y., Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. PLoS One, 5, 2010, 10.1371/journal.pone.0010282 e10282.
201. Snyder, J.W., Greco, W.R., Bellnier, D.A., Vaughan, L., Henderson, B.W., Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res. 1 (2003), 8126–8131.
202. Luo, D., Carter, K.A., Razi, A., Geng, J., Shao, S., Lin, C., Ortega, J., Lovell, J.F., Porphyrin-phospholipid liposomes with tunable leakiness. J. Control. Release 220 (2015), 484–494, 10.1016/j.jconrel.2015.11.011.
203. Mitsunaga, M., Ogawa, M., Kosaka, N., Rosenblum, L.T., Choyke, P.L., Kobayashi, H., Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 17 (2011), 1685–1691, 10.1038/nm.2554.
204. Mitsunaga, M., Nakajima, T., Sano, K., Kramer-marek, G., Choyke, P.L., Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer, 12, 2012, 1, 10.1186/1471-2407-12-345.
205. Kobayashi, H., Choyke, P.L., Super Enhanced Permeability and Retention (SUPR) Effects in Tumors Following Near Infrared Photoimmunotherapy. 2015, 10.1039/c5nr05552k.
206. Sano, K., Nakajima, T., Choyke, P.L., Kobayashi, H., Markedly Enhanced Permeability and Retention Effects Induced by Photo-immunotherapy of Tumors. 2013, 717–724.
207. Liang, C.-P., Nakajima, T., Watanabe, R., Sato, K., Choyke, P.L., Chen, Y., Kobayashi, H., Real-time monitoring of hemodynamic changes in tumor vessels during photoimmunotherapy using optical coherence tomography. J. Biomed. Opt., 19, 2014, 10.1117/1.JBO.19.9.098004 098004–098004.
208. Sakurai, Y., Hada, T., Yamamoto, S., Kato, A., Mizumura, W., Harashima, H., Remodeling of the extracellular matrix by endothelial cell-targeting siRNA improves the EPR-based delivery of 100 nm particles. Mol. Ther. 24 (2016), 2090–2099, 10.1038/mt.2016.178.
209. Eikenes, L., Bruland, O.S., Brekken, C., De Lange Davies, C., Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 64 (2004), 4768–4773, 10.1158/0008-5472.CAN-03-1472.
210. Mckee, T.D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J.P., Bawendi, M.G., Boucher, Y., Breakefield, X.O., Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus Vector. 2006, 2509–2514, 10.1158/0008-5472.CAN-05-2242.
211. Parodi, A., Haddix, X.S.G., Taghipour, X.N., Scaria, S., Taraballi, F., Cevenini, A., Yazdi, I.K., Corbo, C., Palomba, R., Khaled, S.Z., Martinez, J.O., Brown, B.S., Isenhart, L., Tasciotti, E., Bromelain Surface Modification Increases the Diffusion of Silica Nanoparticles in the Tumor Extracellular Matrix. 2014, 9874–9883.
212. Gao, W., Wang, Z., Lv, L., Yin, D., Chen, D., Han, Z., Ma, Y., Zhang, M., Photodynamic therapy induced enhancement of tumor vasculature permeability using an upconversion nanoconstruct for improved intratumoral nanoparticle delivery in deep tissues. Theranostics, 6, 2016, 10.7150/thno.15262.
213. Gaber, M.H., Wu, N.Z., Hong, K., Huang, S.K., Dewhirst, M.W., Papahadjopoulos, D., Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int. J. Radiat. Oncol. Biol. Phys. 36 (1996), 1177–1187, 10.1016/S0360-3016(96)00389-6.
214. Sano, K., Nakajima, T., Choyke, P.L., Kobayashi, H., The Effect of Photoimmunotherapy Followed by Liposomal Daunorubicin in a Mixed Tumor Model: a Demonstration of the Super-enhanced Permeability and Retention Effect after Photoimmunotherapy, vol. 13, 2014, 426–433, 10.1158/1535-7163.MCT-13-0633.
215. Doi, Y., Abu Lila, A.S., Matsumoto, H., Okada, T., Shimizu, T., Ishida, T., Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing. Int. J. Nanomed. 11 (2016), 5573–5582, 10.2147/IJN.S119069.